MorphoSys AG is to stop work on its preclinical research programmes and reduce its workforce in Germany by about 17% in order to marshal resources for its late-stage oncology pipeline. The company announced the decision on 2 March to the Nasdaq and Frankfurt Stock Exchanges where it is listed, alongside a separate press release for investors. MorphoSys is due to report its 2022 fourth quarter and annual results on 15 March.
